Bramante CT et al., 2022-08-18: Phase 3 factorial trial in 1431 overweight or obese US adults with early COVID-19: ivermectin did not prevent hypoxemia, emergency department visits, hospitalization or death (adjusted odds ratio 1.05 for the primary composite).
None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with Covid-19.
Bramante CT et al., 2022-08-18: Phase 3 factorial trial in 1431 overweight or obese US adults with early COVID-19: ivermectin did not prevent hypoxemia, emergency department visits, hospitalization or death (adjusted odds ratio 1.05 for the primary composite). Phase 3, double-blind, randomized, placebo-controlled 2-by-3 factorial trial, N=1431, United States, adults 30-85 with overweight or obesity enrolled within 3 days of diagnosis and less than 7 days of symptoms; ivermectin (per the trial record 400 micrograms/kg daily for 3 days) vs placebo alongside metformin and fluvoxamine arms. Composite adjusted OR for ED visit, hospitalization or death: 1.39 (95% CI 0.72-2.69) with ivermectin; hospitalization or death 0.73 (0.19-2.77). Funded by the Parsemus Foundation and others; NCT04510194. Study type: randomized trial.
